|By Marketwired .||
|June 20, 2014 09:07 AM EDT||
SEATTLE, WASHINGTON -- (Marketwired) -- 06/20/14 -- Ventripoint Diagnostics Ltd. ("Ventripoint") (TSX VENTURE:VPT) announces that it will be exhibiting at the 25th Annual Scientific Sessions hosted by the American Society of Echocardiography (ASE) in Portland, Oregon, held June 20th through June 24th.
"At the ASE this year, the Company will be emphasizing to the echocardiology healthcare professionals the recent FDA clearance of VMS(TM) as substantially equivalent to MRI in patients with Pulmonary Arterial Hypertension (PAH). The VMS(TM) can uniquely demonstrate the ability of echocardiography to be as accurate as MRI. This puts us in an excellent position at this congress to showcase the benefits of the VMS(TM)", stated the CEO of Ventripoint, Dr. George Adams.
Ventripoint will occupy booth #608 in the main exhibition hall and will be distributing demonstration cases to highlight the features of the VMS(TM) to individual cardiologists and research scientists. Those who are unable to attend the ASE 2014, may contact Ventripoint directly at [email protected] to order the VMS(TM) case studies.
"Each year at the ASE we see more time dedicated to presentations concerning RV imaging and analysis. This year the trend continues as the RV is focused on throughout the sessions, from the very first presentation on Saturday titled "Echo in Pulmonary Hypertension", to the very last on Tuesday with "Echo in Heart Failure and Congenital Heart Disease: Imaging that Impacts Management," commented Jim Bodtke, VP Clinical Affairs and Development for Ventripoint. "Being part of the annual ASE Scientific Sessions is the greatest single event we can attend as it gives us direct access to thousands of potential customers, allowing us to demonstrate our product's capabilities to practitioners as well as to the ultrasound manufacturers. We look forward to engaging potential end users of the VMS(TM) and to further developing potential partnerships with world-leading companies to expand our product offerings."
About the American Society of Echocardiography
The American Society of Echocardiography maintains over 16,000 active members annually, with approximately 4,000 of those members participating in the ASE Scientific Sessions. The Scientific Sessions are an educational platform, allowing global leaders in cardiac ultrasound research to present current findings. The Scientific Sessions also provides vendors and manufacturers the opportunity to directly engage the participants and to provide hands-on product demonstrations, as well as networking opportunities to further develop collaboration.
About Ventripoint Diagnostics Ltd.
Ventripoint has created tools to monitor patients with heart disease, a leading cause of death in developed countries. VMS(TM) is the first cost-effective and accurate tool for measuring right ventricle heart function. The Company has a suite of applications for all major heart diseases and imaging modalities including congenital heart disease, left or right heart failure and normal hearts - a multi-billion dollar market potential.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release
FORWARD-LOOKING STATEMENTS: The statements made in this news release that are not historical facts may contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address Ventripoint's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. A description of assumptions used to develop such forward-looking information and a description of risk factors that may cause actual results to differ materially from forward-looking information can be found in Ventripoint's disclosure documents on the SEDAR website at www.sedar.com. The Corporation undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.
Dr. George Adams